相关实验视频

Updated: Feb 24, 2026

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

工程化益生菌Saccharomyces boulardii在小鼠模型中产生具有长效效果的功能性胰岛素

Jefferson J Feng^1,2, Di Yu², Lydia Nyasae¹

¹Fzata Inc., Halethorpe, Maryland, USA.

Biotechnology journal

|February 22, 2026

概括

科学家们设计了一种益生菌酵母,Saccharomyces boulardii,以产生一种功能性胰岛素-Fc融合蛋白,用于口服. 这一突破为糖尿病管理提供了传统胰岛素注射的有希望的替代方案.

科学领域:

生物技术是生物技术.
微生物学微生物学
代谢障碍代谢障碍代谢障碍

背景情况:

糖尿病影响全球超过5亿人,目前的胰岛素注射有局限性.
皮下注射胰岛素可能会损害天然葡萄糖调节,导致患者遵守不良规则.
口服胰岛素输送是可取的,但面临着诸如胃肠道退化和低吸收等挑战.

研究的目的:

为了设计Saccharomyces boulardii用于生产和分泌功能性胰岛素-Fc融合蛋白质.
建立一个可行的平台,使用益生菌酵母提供口服胰岛素.

主要方法:

使用强大的构成性促进剂 (TDH3和TEF1) 进行工程化Saccharomyces boulardii.
创建了一个长期起作用的胰岛素-Fc融合蛋白 (Ins/Fc).
在体外和体内生物模型中验证的表达和生物活性.

主要成果:

在工程化S. boulardii菌株 (FZ030和FZ032) 中实现了Ins/Fc融合蛋白的稳定表达.
细胞培养中分泌的Ins/Fc蛋白的功能生物活性已被证明.
在糖尿病的小鼠模型中确认了生物活性.

结论:

成功设计S. boulardii产生功能性胰岛素,标志着一个重要的进步.
这种益生菌酵母平台显示出开发有效的口服胰岛素输送系统的潜力.
代表了一种新的方法来克服当前糖尿病治疗的局限性.

关键词:

这种植物是Saccharomyces boulardii.生物活性生物活性糖尿病糖尿病患者糖尿病患者胰岛素的胰岛素胰岛素是什么在口服交付口服交付.益生菌是一种益生菌.

更多相关视频

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas

Published on: July 25, 2025

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

相关概念视频

Insulin: Biosynthesis, Chemistry, and Preparation

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...